Microsatellite instability: a review of what the oncologist should know

被引:324
|
作者
Li, Kai [1 ,2 ,3 ]
Luo, Haiqing [3 ]
Huang, Lianfang [1 ,2 ]
Luo, Hui [2 ]
Zhu, Xiao [1 ,2 ]
机构
[1] Guangdong Med Univ, Guangdong Key Lab Res & Dev Nat Drugs, Zhanjiang 524023, Peoples R China
[2] Guangdong Med Univ, Marine Biomed Res Inst, Southern Marine Sci & Engn Guangdong Lab Zhanjian, Zhanjiang 524023, Peoples R China
[3] Guangdong Med Univ, Affiliated Hosp, Ctr Canc, Zhanjiang 524023, Peoples R China
基金
中国国家自然科学基金;
关键词
MSI; Cancer; MSI-H; dMMR; Microsatellite DNA; COLORECTAL-CANCER; MISMATCH-REPAIR; PRACTICE GUIDELINES; CLINICAL-FEATURES; LYNCH SYNDROME; MSI-H; TUMOR; CARCINOMA; RISK; GENE;
D O I
10.1186/s12935-019-1091-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The patients with high microsatellite instability (MSI-H)/mismatch repair deficient (dMMR) tumors recently have been reported that can benefit from immunotherapy, and MSI can be used as a genetic instability of a tumor detection index. However, many studies have shown that there are many heterogeneous phenomena in patients with MSI tumors in terms of immunotherapy, prognosis and chemotherapy sensitivity. Here we mainly review the research results of MSI detection methods, the mechanisms of MSI occurrence and its relationship with related tumors, aiming to make a brief analysis of the current research status of MSI and provide comparable reference and guidance value for further research in this field.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Microsatellite instability: a review of what the oncologist should know
    Kai Li
    Haiqing Luo
    Lianfang Huang
    Hui Luo
    Xiao Zhu
    Cancer Cell International, 20
  • [2] Biosimilars: what the oncologist should know
    Thill, Marc
    Thatcher, Nicholas
    Hanes, Vladimir
    Lyman, Gary H.
    FUTURE ONCOLOGY, 2019, 15 (10) : 1147 - 1165
  • [3] Pharmacogenomics in Lung Cancer Chemotherapy: A Review of What the Oncologist Should Know
    D'Antonio, Chiara
    Milano, Annalisa
    Righini, Riccardo
    Onesti, Concetta Elisa
    Bassanelli, Maria
    Falcone, Rosa
    Paris, Ida
    Lauro, Salvatore
    Marchetti, Paolo
    ANTICANCER RESEARCH, 2014, 34 (10) : 5241 - 5250
  • [4] Inflammation and cancer: What a surgical oncologist should know
    Dupre, Aurelien
    Malik, Hassan Z.
    EJSO, 2018, 44 (05): : 566 - 570
  • [5] Imaging and diagnostic approach of the adnexal mass: what the oncologist should know
    Vazquez-Majarrez, Sara E.
    Rico-Rodriguez, O. Cristina
    Guzman-Martinez, Nancy
    Espinoza-Cruz, Veronica
    Lara-Nunez, Denny
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (05)
  • [6] Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know
    Habre, Maya
    Habre, Samer Bassilios
    Kourie, Hampig R.
    IMMUNOTHERAPY, 2016, 8 (12) : 1437 - 1446
  • [7] WHAT A MEDICAL/SURGICAL ONCOLOGIST SHOULD KNOW OF COLORECTAL HEREDITARY SYNDROMES
    Bulow, S.
    ANNALS OF ONCOLOGY, 2010, 21 : I16 - I16
  • [8] What every surgical oncologist should know about digital mammography
    Pisano, ED
    Kuzmiak, C
    Koomen, M
    Cance, W
    SEMINARS IN SURGICAL ONCOLOGY, 2001, 20 (03): : 181 - 186
  • [9] Genetic Biomarkers in Melanoma of the Ocular Region: What the Medical Oncologist Should Know
    Bol, Kalijn Fredrike
    Donia, Marco
    Heegaard, Steffen
    Kiilgaard, Jens Folke
    Svane, Inge Marie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 14
  • [10] Microsatellite instability-What should be considered in routine examinations?
    Dietmaier, Wolfgang
    Hirsch, Daniela
    Rueschoff, Josef
    PATHOLOGIE, 2025, 46 (02): : 122 - 125